Vera Therapeutics Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company, reported its financial results for the second quarter ended June 30, 2025. The company experienced a net loss of $76.5 million, or a net loss per diluted share of $1.20. This represents a significant increase from the net loss of $33.7 million, or a net loss per diluted share of $0.62, recorded for the same quarter in 2024. During the first six months of 2025, net cash used in operating activities was $109.2 million, compared to $58.6 million for the same period in the previous year. Vera Therapeutics announced positive primary endpoint results from its ongoing ORIGIN Phase 3 trial and is on track to submit a Biologics License Application $(BLA.AU)$ for accelerated approval of atacicept to the U.S. FDA in the fourth quarter of 2025. The company anticipates a potential commercial launch of atacicept in 2026. Vera reported holding $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which it believes to be sufficient to fund operations through the potential approval and U.S. commercial launch of atacicept and beyond.